1
|
Shimada T, Maetani T, Chubachi S, Tanabe N, Asakura T, Namkoong H, Tanaka H, Azekawa S, Otake S, Nakagawara K, Fukushima T, Watase M, Shiraishi Y, Terai H, Sasaki M, Ueda S, Kato Y, Harada N, Suzuki S, Yoshida S, Tateno H, Shimizu K, Sato S, Yamada Y, Jinzaki M, Hirai T, Okada Y, Koike R, Ishii M, Kimura A, Imoto S, Miyano S, Ogawa S, Kanai T, Fukunaga K. Erector Spinae Muscle to Epicardial Visceral Fat Ratio on Chest CT Predicts the Severity of Coronavirus Disease 2019. J Cachexia Sarcopenia Muscle 2025; 16:e13721. [PMID: 39868664 PMCID: PMC11770476 DOI: 10.1002/jcsm.13721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2024] [Revised: 10/07/2024] [Accepted: 12/25/2024] [Indexed: 01/28/2025] Open
Abstract
BACKGROUND Chest computed tomography (CT) is a valuable tool for diagnosing and predicting the severity of coronavirus disease 2019 (COVID-19) and assessing extrapulmonary organs. Reduced muscle mass and visceral fat accumulation are important features of a body composition phenotype in which obesity and muscle loss coexist, but their relationship with COVID-19 outcomes remains unclear. In this study, we aimed to investigate the association between the erector spinae muscle (ESM) to epicardial adipose tissue (EAT) ratio (ESM/EAT) on chest CT and disease severity in patients with COVID-19. METHODS We analysed data from 1074 COVID-19 patients enrolled in the Japan COVID-19 Task Force database. The primary outcome was the rate of critical outcomes (requiring high-flow oxygen therapy, invasive ventilator support or death). The incidence of critical outcomes was compared between patients with high and low ESM/EAT ratios. RESULTS The low ESM/EAT group (n = 353) had a higher incidence of critical outcomes (13.3% vs. 5.13%, p < 0.001) and mortality (2.55% vs. 0.69%, p = 0.019) than the high ESM/EAT group (n = 721). In multivariable analysis, the low ESM/EAT ratio was associated with critical outcomes (adjusted odds ratio [aOR] 2.11, 95% confidence interval [CI] 1.22-3.66) independently of the known COVID-19 severity factors including age, sex, body mass index (BMI), smoking history, lifestyle-related comorbidities and pneumonia volume. CONCLUSION The low ESM/EAT ratio in COVID-19 patients can be obtained on chest CT and used to predict critical outcomes after disease onset, demonstrating the importance of detailed body composition assessments in COVID-19 practice.
Collapse
Affiliation(s)
- Takashi Shimada
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
| | - Tomoki Maetani
- Department of Respiratory Medicine, Graduate School of MedicineKyoto UniversityKyotoJapan
| | - Shotaro Chubachi
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
| | - Naoya Tanabe
- Department of Respiratory Medicine, Graduate School of MedicineKyoto UniversityKyotoJapan
| | - Takanori Asakura
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
- Department of Clinical Medicine (Laboratory of Bioregulatory Medicine)Kitasato University School of PharmacyTokyoJapan
- Department of Respiratory Medicine, Kitasato UniversityKitasato Institute HospitalTokyoJapan
| | - Ho Namkoong
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
- Department of Infectious DiseasesKeio University School of MedicineTokyoJapan
| | - Hiromu Tanaka
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
| | - Shuhei Azekawa
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
| | - Shiro Otake
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
| | - Kensuke Nakagawara
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
| | - Takahiro Fukushima
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
| | - Mayuko Watase
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
| | - Yusuke Shiraishi
- Department of Respiratory Medicine, Graduate School of MedicineKyoto UniversityKyotoJapan
| | - Hideki Terai
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
| | - Mamoru Sasaki
- Internal MedicineJCHO (Japan Community Health Care Organization) Saitama Medical CenterSaitamaJapan
| | - Soichiro Ueda
- Internal MedicineJCHO (Japan Community Health Care Organization) Saitama Medical CenterSaitamaJapan
| | - Yukari Kato
- Department of Respiratory MedicineJuntendo University Faculty of Medicine and Graduate School of MedicineTokyoJapan
| | - Norihiro Harada
- Department of Respiratory MedicineJuntendo University Faculty of Medicine and Graduate School of MedicineTokyoJapan
| | - Shoji Suzuki
- Department of Pulmonary MedicineSaitama City HospitalSaitamaJapan
| | - Shuichi Yoshida
- Department of Pulmonary MedicineSaitama City HospitalSaitamaJapan
| | - Hiroki Tateno
- Department of Pulmonary MedicineSaitama City HospitalSaitamaJapan
| | - Kaoruko Shimizu
- Department of Respiratory Medicine, Graduate School of MedicineHokkaido UniversitySapporoJapan
| | - Susumu Sato
- Department of Respiratory Medicine, Graduate School of MedicineKyoto UniversityKyotoJapan
- Department of Respiratory Care and Sleep Control Medicine, Graduate School of MedicineKyoto UniversityKyotoJapan
| | - Yoshitake Yamada
- Department of RadiologyKeio University School of MedicineTokyoJapan
| | - Masahiro Jinzaki
- Department of RadiologyKeio University School of MedicineTokyoJapan
| | - Toyohiro Hirai
- Department of Respiratory Medicine, Graduate School of MedicineKyoto UniversityKyotoJapan
| | - Yukinori Okada
- Department of Statistical GeneticsOsaka University Graduate School of MedicineSuitaJapan
- Department of Genome Informatics, Graduate School of MedicineThe University of TokyoTokyoJapan
- Laboratory for Systems GeneticsRIKEN Center for Integrative Medical SciencesYokohamaKanagawaJapan
| | - Ryuji Koike
- Health Science Research and Development CenterTokyo Medical and Dental UniversityTokyoJapan
| | - Makoto Ishii
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
- Department of Respiratory MedicineNagoya University Graduate School of MedicineNagoyaJapan
| | - Akinori Kimura
- Institute of ResearchTokyo Medical and Dental UniversityTokyoJapan
| | - Seiya Imoto
- Division of Health Medical Intelligence, Human Genome Center, Institute of Medical ScienceUniversity of TokyoTokyoJapan
| | - Satoru Miyano
- M&D Data Science CenterTokyo Medical and Dental UniversityTokyoJapan
| | - Seishi Ogawa
- Department of Pathology and Tumor BiologyKyoto UniversityKyotoJapan
- Institute for the Advanced Study of Human Biology (WPI‐ASHBi)Kyoto UniversityKyotoJapan
| | - Takanori Kanai
- Division of Gastroenterology and Hepatology, Department of Internal MedicineKeio University School of MedicineTokyoJapan
| | - Koichi Fukunaga
- Division of Pulmonary Medicine, Department of MedicineKeio University School of MedicineTokyoJapan
| |
Collapse
|
2
|
Watase M, Shiraishi Y, Chubachi S, Tanabe N, Maetani T, Asakura T, Namkoong H, Tanaka H, Shimada T, Azekawa S, Otake S, Fukushima T, Nakagawara K, Masaki K, Terai H, Mochimaru T, Sasaki M, Ueda S, Kato Y, Harada N, Suzuki S, Yoshida S, Tateno H, Yamada Y, Jinzaki M, Okada Y, Koike R, Ishii M, Kimura A, Imoto S, Miyano S, Ogawa S, Kanai T, Fukunaga K. Coronary Artery Calcification on Chest Computed Tomography as a Predictor of Cardiovascular Adverse Events in Patients With COVID-19 - A Multicenter Retrospective Study in Japan. Circ J 2025:CJ-24-0661. [PMID: 39828330 DOI: 10.1253/circj.cj-24-0661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2025]
Abstract
BACKGROUND Coronary artery calcification (CAC) detected through chest computed tomography (CT) strongly predicts cardiovascular events in asymptomatic individuals undergoing primary prevention. Few studies with limited sample sizes have investigated the predictive value of CAC for cardiovascular complications in COVID-19. This study examined the impact of CAC on cardiovascular complications using a large-scale COVID-19 database. METHODS AND RESULTS This multicenter retrospective cohort study used data from the Japan COVID-19 Task Force database. After exclusion based on missing information, 1,109 patients with COVID-19 were included. The Agatston score was used to evaluate CAC, dividing the population into 3 groups based on calcification degree (no, moderate, and severe CAC). The primary outcome was cardiovascular complications; the secondary outcome was critical outcomes. The severe CAC group had a higher rate of cardiovascular complications than the other groups. Multivariable analysis, considering COVID-19 severity factors, identified severe CAC as independently associated with cardiovascular complications but not with critical outcomes. Subgroup analysis revealed that, in patients without hypertension, diabetes, cardiovascular disease, or chronic kidney disease, severe CAC was significantly correlated with cardiovascular complications, whereas this association was not observed in patients with these underlying conditions. CONCLUSIONS Patients with COVID-19 and severe CAC had increased cardiovascular complications, and identifying cardiovascular and pulmonary findings on chest CT is essential. Measuring CAC via non-electrocardiogram-gated CT helps predict patient risk.
Collapse
Affiliation(s)
- Mayuko Watase
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
- Department of Respiratory Medicine, National Hospital Organization, Tokyo Medical Center
| | - Yusuke Shiraishi
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
| | - Shotaro Chubachi
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
| | - Naoya Tanabe
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
| | - Tomoki Maetani
- Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University
| | - Takanori Asakura
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
- Laboratory of Bioregulatory Medicine, Department of Clinical Medicine, Kitasato University School of Pharmacy
- Department of Respiratory Medicine, Kitasato University, Kitasato Institute Hospital
| | - Ho Namkoong
- Department of Infectious Diseases, Keio University School of Medicine
| | - Hiromu Tanaka
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
| | - Takashi Shimada
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
| | - Shuhei Azekawa
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
| | - Shiro Otake
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
| | - Takahiro Fukushima
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
| | - Kensuke Nakagawara
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
| | - Katsunori Masaki
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
| | - Hideki Terai
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
| | - Takao Mochimaru
- Department of Respiratory Medicine, National Hospital Organization, Tokyo Medical Center
| | - Mamoru Sasaki
- Department of Respiratory Medicine, Japan Community Health Care Organization (JCHO), Saitama Medical Center
| | - Soichiro Ueda
- Department of Respiratory Medicine, Japan Community Health Care Organization (JCHO), Saitama Medical Center
| | - Yukari Kato
- Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine
| | - Norihiro Harada
- Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine
| | - Shoji Suzuki
- Department of Pulmonary Medicine, Saitama City Hospital
| | | | - Hiroki Tateno
- Department of Pulmonary Medicine, Saitama City Hospital
| | | | | | - Yukinori Okada
- Department of Statistical Genetics, Osaka University Graduate School of Medicine
- Department of Genome Informatics, Graduate School of Medicine, University of Tokyo
- Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences
| | - Ryuji Koike
- Health Science Research and Development Center (HeRD), Tokyo Medical and Dental University
| | - Makoto Ishii
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
- Department of Respiratory Medicine, Nagoya University Graduate School of Medicine
| | - Akinori Kimura
- Institute of Research, Tokyo Medical and Dental University
| | - Seiya Imoto
- Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo
| | - Satoru Miyano
- M&D Data Science Center, Tokyo Medical and Dental University
| | - Seishi Ogawa
- Department of Pathology and Tumor Biology, Kyoto University
- Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University
| | - Takanori Kanai
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine
| | - Koichi Fukunaga
- Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine
| |
Collapse
|
3
|
Katić A, Rizvanović N. Predictive significance of hypertension in the incidence of complications in critically ill patients with COVID‑19: A retrospective cohort study. MEDICINE INTERNATIONAL 2024; 4:74. [PMID: 39483927 PMCID: PMC11526207 DOI: 10.3892/mi.2024.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/28/2024] [Accepted: 09/30/2024] [Indexed: 11/03/2024]
Abstract
The association between hypertension as a pre-existing comorbidity and the severe form of coronavirus disease 2019 (COVID-19) remains unclear due to the contradictory results of previously published studies. The present study evaluated the predictive significance of hypertension in the incidence of complications among critically ill patients with COVID-19. The present study included 372 critically ill adults with COVID-19 pneumonia, hospitalized between January 1 and December 31, 2021. The study cohort was divided into the hypertension group (HTA group), which included 245 patients with a history of hypertension, or a non-HTA group (control group), which included 127 patients without hypertension. The incidence of complications was retrospectively extracted from medical records and compared between groups. Multivariate regression analysis (adjusted for potential confounders) and receiver operating characteristic (ROC) curve analysis determined the predictive significance of hypertension on the incidence of complications. The patients in the HTA group were more likely to receive invasive mechanical ventilation [odds ratio (OR), 1.696; P<0.02], develop sepsis (OR, 1.807; P<0.01) and develop complications (OR, 3.101; P<0.001). Hypertension was an independent positive predictor for invasive mechanical ventilation [area under the curve (AUC), 0.67; positive predictive value (PPV), 71.7%; P<0.05], sepsis (AUC, 0.69; PPV, 77.5%; P<0.026) and total complications per patient (AUC, 0.71; PPV, 81.4%; P<0.001). On the whole, the data of the present study indicate that a history of hypertension should be considered as an independent clinical predictor of a higher incidence of complications in critically ill patients with COVID-19. Patients with pre-existing hypertension and a diagnosis of COVID-19 require timely identification, additional attention and treatment to avoid a critical course and help improve outcomes.
Collapse
Affiliation(s)
- Anita Katić
- Practice of Dr Nada Vukicevic General Medicine, D-88662 Überlingen, Germany
| | - Nermina Rizvanović
- Department of Anesthesiology, Resuscitation and Intensive Care, Cantonal Hospital Zenica, University of Zenica, Faculty of Medicine, 72000 Zenica, Bosnia and Herzegovina
| |
Collapse
|